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ABSTRACT: Mycobacterium tuberculosis (MTb) possesses two nonproton pumping type II NADH dehydrogenase (NDH-2)
enzymes which are predicted to be jointly essential for respiratory metabolism. Furthermore, the structure of a closely related bacterial
NDH-2 has been reported recently, allowing for the structure-based design of small-molecule inhibitors. Herein, we disclose MTb
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Tuberculosis (TB) is a major global health problem, resultingin signiﬁcant morbidity each year. Although mortality has
fallen dramatically since 1990, TB now ranks alongside HIV as a
leading cause of death worldwide. While HIV-related deaths have
been declining largely as a result of improved access to, and avail-
ability of, better HIV treatments, this has not been the case for
TB,1 the treatment of which requires 6 months of chemotherapy
with a combination of four agents (isoniazid, rifampicin, pyra-
zinamide, and ethambutol) to achieve durable cure of drug-
sensitive TB.2 The large number of TB patients, coupled with the
chemotherapeutic burden, often leads to poor patient adherence
and suboptimal treatment outcomes in the developing world, as
well as the emergence of multidrug resistant TB (MDR-TB,
deﬁned as resistance to isoniazid (INH) and rifampicin (RIF))
and extensively drug-resistant tuberculosis (XDR-TB, deﬁned as
MDR-TB plus resistance to any ﬂuoroquinolone and one of three
second-line injectable drugs, capreomycin, kanamycin (Kan), and
amikacin). To address this global TB health problem, an improved
treatment regimen is needed which will reduce treatment dura-
tion and prevent relapse and the development of TB drug resis-
tance.3−8 However, achieving this goal will require discovery of
multiple novel andmechanistically distinct antimycobacterial agents
possessing reduced liabilities for investigation of new drug regimens
that might shorten the duration of treatment and simplify manage-
ment of the disease by improving adherence and reducing costs.9−12
Identiﬁcation of novel drug targets that will lead to treatment
shortening is challenging. Targets of drugs currently in use or
phase 3 clinical evaluation for TB chemotherapy include cell wall
biosynthesis, translation, transcription, folate synthesis, ATP gen-
eration, and maintenance of DNA topology as broad categories,
although the nitroimidazoles delaminid and pretomanid generate
reactive nitrogen intermediates that inhibit several essential pro-
cesses.13 Mechanistically novel drugs would conceptually target
distinct processes from the above, and to date, successes in the
ﬁeld have all emerged from target identiﬁcation of hits discovered
in Mycobacterium tuberculosis (MTb) whole cell screens.13
In this work, we describe the identiﬁcation of a 2-mercapto-
quinazoline scaﬀold identiﬁed from aMTbwhole cell screen, which
had been previously reported to inhibit the mycobacterial type II
NADH dehydrogenase,14 providing further evidence for its inhi-
bition of theMTb type II NADHdehydrogenase (NDH-2).MTb
encodes two NDH-2 genes of which the one encoded by ndh
plays a critical role for growth both in vitro and in vivo.15−17
NDH-2 catalyzes the transfer of electrons from NADH into the
mycobacterial respiratory pathway and has been proposed to be
targeted by a number of early stage inhibitors.16,18−20 In contrast,
the proton pumping type I NADHdehydrogenase can be deleted
without apparent eﬀects on growth both in vitro or in vivo.15−17
As the current series was considered to have a promising drug-
like proﬁle (Table 1), a focused optimization programwas initiated.
■ RESULTS AND DISCUSSION
Screening of a commercial diversity library, details of which will
be published elsewhere, aﬀorded a 2-mercapto-quinazolinone
whole-cell structure−activity relationships (SARs) for a series of 2-mercapto-quinazolinones which target the ndh encoded NDH-2
with nanomolar potencies. The compounds were inactivated by glutathione-dependent adduct formation as well as quinazolinone
oxidation in microsomes. Pharmacokinetic studies demonstrated modest bioavailability and compound exposures. Resistance to the
compounds in MTb was conferred by promoter mutations in the alternative nonessential NDH-2 encoded by ndhA in MTb.
Bioenergetic analyses revealed a decrease in oxygen consumption rates in response to inhibitor in cells in which membrane potential
was uncoupled from ATP production, while inverted membrane vesicles showed mercapto-quinazolinone-dependent inhibition of
ATP production when NADH was the electron donor to the respiratory chain. Enzyme kinetic studies further demonstrated
noncompetitive inhibition, suggesting binding of this scaﬀold to an allosteric site. In summary, while the initial MTb SAR showed
limited improvement in potency, these results, combined with structural information on the bacterial protein, will aid in the future
discovery of new and improved NDH-2 inhibitors.
KEYWORDS: Mycobacterium tuberculosis, mercapto-quinazolinones, structure−activity relationship, type II NADH dehydrogenase,
small molecule NDH-2 inhibitors, respiration
Table 1. Proﬁling of Conﬁrmed Hits 1, 2, and 3
aCalculated using StarDrop (http://www.optibrium.com). bKinetic aqueous solubility was measured using laser nephelometry of compounds in
2.5% DMSO.
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cluster of hits (1, 2, and 3), with compounds 1 and 2 showing
potentMTb whole-cell minimum inhibitory concentration (MIC)
in two distinct growth media. The compounds were assessed in a
series of early stage biology proﬁling assays to understand better
the mechanism of action (MoA). These included screening the
compounds against a cyd knockout strain which is known to be
hyper-susceptible to inhibitors of the cytochrome bc1 complex,
21
which suggested that the series was unlikely to target QcrB. Pro-
ﬁling also investigated the extent of upregulation of the promoter
of the iniBAC gene cluster, known to be induced by inhibitors of
cell wall biosynthesis, such as isoniazid, ethionamide, SQ109, and
ethambutol,22,23 which suggested 1 and 2 did not have an eﬀect
on cell wall biosynthesis. These biology proﬁling data were con-
sidered promising, especially in conjunction with a recent report14
in which mutations in MTb mutants spontaneously resistant to
compound 1 mapped to ndhA, the gene encoding the non-
essential type-II NADH dehydrogenase that is involved in NADH
reoxidation in the mycobacterial oxidative phosphorylation path-
way.14 There are two closely related nonproton pumping type II
NADH dehydrogenases in the MTb genome, of which only one
(encoded by ndh, Rv1854c) is essential.24−27 Ioerger et al.14 iden-
tiﬁed promoter mutations in ndhA which resulted in >40-fold
upregulation of gene expression, likely compensating for
compound 1 inhibiting the essential NDH-2 homologue.
Compound 1 had a promising MTb MIC-derived ligand-
lipophilicity eﬃciency (LLE) drug-likeness proﬁle, suggestive of
a quality starting point for medicinal chemistry optimization.28,29
Compound 1 also showed no noticeable cytotoxicity in a mam-
malian cell line (HepG2). Compounds 1 and 2 also had moderate
kinetic solubility and reasonable mouse hepatic microsomal stabil-
ity, with 1 having excellent human microsomal stability (Table 1).
Herein, we report on the development of the structure−activity
relationship (SAR) for 1, as well as extended absorption, distri-
bution, metabolism, and excretion (ADME) characterization of
key compounds.
Synthetic Chemistry.Quinazolinone amides reported herein
were synthesized utilizing known procedures, which are detailed
in Scheme 1. Commercially available anthranilic acids (28) were
cyclized with thiourea, and the resulting 2-mercapto quinazoline-
4-diones (29) or commercially available 2-mercapto-4(3H)-
quinazolinone was reacted with 2-bromo acetic acid to form the
2-((4-oxo-3,4-dihydroquinazolin-2-yl)thio)acetic acids (30). Pri-
mary and secondary amines (31) were coupled using standard
coupling reagents to aﬀord compounds 1, 2, 4−11, and 14.
MTb Whole-Cell SAR. The initial medicinal chemistry plan
focused on developing the SAR with the aim of better under-
standing the pharmacophore. Initial eﬀorts were guided by mouse
microsomal metabolite identiﬁcation (met-ID) studies on 1, which
revealed signiﬁcant oxidation of the cyclohexyl and quinazolin-
4(3H)-one rings as well as cleavage of the amide bond (Figure S1).
To understand the scope, cycloalkyls 4, 5, and 6 were prepared
(Table 2). The large bulky lipophilic cyclohexyl 1 and
cycloheptyl 4 were both equally favored, with good whole-cell
MIC potency. In contrast, the smaller ring-contracted cyclo-
pentyl 5 and cyclobutyl 6 were slightly less potent (Table 2), and
the cyclopropyl and ring deletion NHMe analogues (data not
shown) resulted in a complete loss of whole-cell activity, sug-
gesting that a bulky hydrophobic group was required to obtain
good whole-cell potency. As mouse met-ID of 1 showed signif-
icant oxidation of the cyclohexyl group, the 2-, 3-, and 4-hydroxylated
cyclohexyl derivatives were prepared with the aim of improving
solubility as well as microsomal stability. Improvements in both
kinetic solubility and mouse microsomal stability were indeed
achieved, but nowhole-cell activity was observed (data not shown).
An additional focused set of polar saturated 4-, 5-, and 6-membered
oxygen-containing saturated heterocycles was prepared; how-
ever, while having good kinetic solubility and mouse microsomal
stability, they too lost all whole-cell activity (data not shown).
Scheme 1. General Synthetic Route for Synthesis of Quinazolinone Amidesa
aReagents and conditions: General synthetic approach to quinazolinones 1, 2, 4−11, and 14: (a) neat thiourea at 180 °C, 3 h; (b) 2-bromoacetic
acid, triethylamine, DMF, 80 °C, 12 h; (c) primary and/or secondary amine 31, EDC·HCl, HOAT, N,N-diisopropylethylamine, DMF/ACN (1:1),
room temperature, 12 h or primary and/or secondary amine 31, HATU, N,N-diisopropylethylamine, DCM, room temperature, 12 h.
Table 2. Evaluation R1 (Cyclohexyl) SAR
aMinimum inhibitory concentration (MIC) is the minimum
concentration required to inhibit >99% growth of M. tuberculosis in
liquid culture. Isoniazid was included as an internal control reference
compound (MIC of 0.2 ± 0.1 μM). bIntrinsic clearance (Cli) using
CD1 mouse liver microsomes. cKinetic aqueous solubility was
measured using laser nephelometry of compounds in 2.5% DMSO.
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There were also attempts to improve solubility with diﬀerentially
functionalized 4-substituted piperidines (NAc, NSO2Me, NMe,
and NBn), but once again, there was a loss of whole-cell activity
(data not shown). As the cyclohexyl group within 1 did not appear
to tolerate polar solubilizing groups, we turned our focus to intro-
ducing ﬂuorine in an attempt to improve microsomal stabil-
ity.30,31 We were encouraged to ﬁnd that the 4,4-diﬂuorocyclo-
hexan 7 retained good whole-cell potency and also had slightly
improved mouse microsomal stability versus 1. In comparison
to 1, mouse microsomal met-ID on 7 showed a small amount of
amide bond cleavage as well as oxidation of the quinazolin-
4(3H)-one ring (Figure S2). The 2,2- and 3,3-diﬂuorocyclohex-
an compounds 8 and 9 hadmoderate to poor whole-cell potency.
Met-ID for both 1 and 7 revealed cleavage of the amide bond, so
attempts to hinder the amide through formation of the 1-methyl-,
1-methanol-, and 1-cyano-substituted cyclohexane were explored,
all of which resulted in a complete loss of MIC potency as well as
increased mouse microsomal instability (data not shown). Addi-
tion of a methylene bridge in 1 and 7 to aﬀord 10 and 11 improved
MIC potency, further emphasizing the requirement for bulky
lipophilic groups.
There were concerns over the S-linker, based on previous
experience from whole-cell screening where conﬁrmed hits with
similar S-linker compounds were found to react with glutathione
(GSH) both with and without microsomal activation. GSH trap-
ping on 7, with and without human liver microsomes (Figure S3),
showed GSH adducts 12 and 13, without microsomal activation.
It is presumed that GSH results in cleavage of the sulfur-
quinazolinone 7 linker, to aﬀord 12, with GSH coupling to the
displaced S-linker to aﬀord 13. Human microsomal oxidation of
the quinazolinone ring of 7 was also observed (see Figure 1).
While the level of GSH adduct formation for 7 was relatively
low and no HepG2 cytotoxicity was observed, this was consid-
ered a liability of the series as the reactivity did not require
microsomal activation and the ability to predict and quantify
the risk of idiosyncratic adverse drug reactions is limited.32,33
We attempted to reduce this liability by modifying the linker.
N-Methylation of the amide and/or themethylene linker to aﬀord
14, 15, and 16, was not tolerated. The NH-, O-, and CH2-linkers
were readily prepared to aﬀord 17, 18, and 19. However, all
resulted in a loss of MIC potency (see Table 3). Oxidation of
S-atom in compound 1 was attempted using a variety of conditions
and oxidation reagents (for example, 3-chlorobenzoic acid, potas-
sium permanganate, and Oxone). However, all attempts failed to
deliver the desired sulfone, possibly as a result of increased reactivity.
Changes to the quinazolinone ring were then explored,
starting with N-methylation to aﬀord 20, which was not
tolerated. Removal of the carbonyl, by synthesis of quinazoline
21 and quinazolin-4-amine 22, was also not tolerated. Saturation
of the quinazolinone core phenyl aﬀorded 23, which retained
good MIC potency and also resulted in improved solubility,
albeit microsomal stability was poor. The related 5-membered
saturated analogue 24 showed similar MIC potency but with
improved microsomal stability as well as solubility. However, the
dimethyl analogue 25 was less well tolerated, suggesting that a
bulky hydrophobic ring was preferred. The above SAR suggested
that the pyrimidinone core was a key part of the pharmacophore.
As human-metID showed oxidation of the quinazolinone ring of 7,
we synthesized the presumably more stable ﬂuorine analogue 26
which, while not as potent as 7, retained good MIC potency.
However, the solubility was poor, and the mouse microsomal
stability was moderate. In an attempt to improve solubility as well
as microsomal stability, the pyridopyrimidinone 27 was pre-
pared; while solubility and microsomal stability were improved,
the compound had moderate to weak MIC potency. A summary
of the overall whole-cell SAR for 1, as well as the eﬀects on both
kinetic solubility and microsomal stability, is shown in Figure 2
and in Tables 2−4.
Pharmacokinetic studies were initiated in order to assess
the potential for in vivo eﬃcacy studies of the 2-mercapto-
quinazolinones. Compound 1, when dosed as the free base, had
reasonable bioavailability, consistent with its moderate Cli and
solubility, and good permeability (Table 5). Compound 7 showed
a similar bioavailability and exposure proﬁle to 1 (Table 5).
As compound 7 had comparable MIC potency, mouse micro-
somal stability, and pharmacokinetic proﬁle to 1, a dose linearity
study was conducted to evaluate if exposures above the MIC
could be achieved. However, no dose linearity was observed
between the 30 and 100 mg/kg doses, determined by the area
under the curve (AUC) comparison (Figure S4). This may be a
consequence of solubility limited absorption at the highest dose.
Compound 11 demonstrated better kinetic solubility and com-
parable MIC to compounds 1 and 7, yet despite an improved
Cmax and Tmax compared to compound 1, likely driven by its
improved kinetic solubility, it had a lower exposure (AUC) over
time (Figure S5 and Table 5), likely a consequence of it is higher
clearance (mouse Cli 4.7 mL/min/g versus 2.3 or 1.4 for
compounds 1 and 7, respectively). The modest compound
exposures upon oral dosing, combined with the lack of ex vivo
intramacrophage eﬃcacy (vide inf ra), suggested that eﬃcacy stud-
ies of these compounds in infected mice were unlikely to validate
the target/drug candidate pair in an animal model where the
disease is macrophage-based. As such, an eﬃcacy experiment was
not performed.
Figure 1. Metabolite identiﬁcation of 7 in a GSH trapping experiment.
ACS Infectious Diseases Article
DOI: 10.1021/acsinfecdis.7b00275
ACS Infect. Dis. 2018, 4, 954−969
957
Biological Characterization of the Mercapto-Quinazo-
linones. Previous work on a mercapto-quinazolinone had
suggested that compound 1might target NDH-2 as evidenced by
promoter mutations in the nonessential ndhA gene encoding an
orthologue of the type II NADH dehydrogenase.14 We similarly
identiﬁed promoter mutations for ndhA but were not able to
identify polymorphisms in the apparently essential ndh (Rv1854c)
(Table S1) suggesting either that mutations were deleterious for
enzyme function or that single amino acid mutations alone might
not suﬃciently decrease aﬃnity of this putative inhibitor. The
upregulation of ndhA could serve to compensate for loss of NDH-2
function or could serve to bind excess inhibitor in the cell. It is
intriguing that ndh promoter mutations were not identiﬁed pos-
sibly because this gene is not readily upregulated by single nucle-
otide substitutions in its promoter. We also identiﬁed mutations
in Rv0678 (Table S1) encoding a transcriptional repressor that
has previously been demonstrated to control expression of the
MmpS5-MmpL5 transporter and has been implicated in
resistance to bedaquiline and clofazimine.34 In accordance with
the predicted essential role of NDH-2 as complex I in oxidative
phosphorylation,16 treatment ofMTb with compound 1 resulted
in depletion of cellular ATP levels, a phenomenon also observed
with bedaquiline (TM207), an inhibitor of the ATP synthase, as
well as EU306, an inhibitor of the cytochrome bc1 complex
35 but
not with inhibitors of macromolecular biosynthesis including
INH (cell wall), Rif (RNA polymerase), and Kan (protein syn-
thesis) (Figure 3).
We predicted that inhibition of NDH-2 would result in a more
severe phenotype on a mutant lacking the second copy of
the type II NADH dehydrogenase. Indeed, while treatment of
wild-type MTb H37Rv at MIC concentrations could not
fully suppress growth of cells over 7 days of treatment, similar
Table 3. Evaluation of S-Linker SAR
aMinimum inhibitory concentration (MIC) is the minimum
concentration required to inhibit >99% growth of M. tuberculosis in
liquid culture. Isoniazid was included as an internal control reference
compound (MIC of 0.2 ± 0.1 μM). bIntrinsic clearance (Cli) using
CD1 mouse liver microsomes. cKinetic aqueous solubility was
measured using laser nephelometry of compounds in 2.5% DMSO.
Figure 2. Overview of structure−activity and property relationships of the mercapto-quinazolinones.
Table 4. Evaluation of Quinazolinone Core
aMinimum inhibitory concentration (MIC) is the minimum
concentration required to inhibit >99% growth of M. tuberculosis in
liquid culture. Isoniazid was included as an internal control reference
compound (MIC of 0.2 ± 0.1 μM). bIntrinsic clearance (Cli) using
CD1 mouse liver microsomes. cKinetic aqueous solubility was
measured using laser nephelometry of compounds in 2.5% DMSO.
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concentrations of compound resulted in an almost 2-log kill
of a ΔndhA mutant (Figure 4). Despite the higher vulnerability
of the ndhA mutant to killing by compound 1, the MIC to
this strain, as well as a nuoG deletion mutant lacking a functional
type I NADH dehydrogenase, was indistinguishable from WT
cells (results not shown). Inhibition of anaerobic nonreplicating
cells with compound 1 did not aﬀect viability (Figure S6) which
contrasts with the anaerobic cidal activity of other NDH-2
inhibitors including the phenothiazines16 and a recently
described quinolone scaﬀold,19 possibly due to diﬀerences in
compound access to the target under anaerobic conditions or to
growth-dependent diﬀerences in compound modiﬁcation by
MTb. In addition, this compound lacked activity against MTb
growing in infected macrophages (Figure S7) possibly due
GSH-catalyzed compound inactivation or inability to access the
mycobacterial phagosome.
The eﬀect of the mercapto-quinazolinones on MTb bio-
energetics in whole cells was further demonstrated by analysis of
the mycobacterial oxygen consumption rate (OCR) (Figure 5).
Addition of compounds 1 and 7 had aminimal eﬀect on basalMTb
OCR levels over ∼45 min. The same results were obtained in the
presence of glucose or palmitate as carbon sources (Figure 5A,B).
Uncoupling ofMTb oxidative phosphorylation (OXPHOS) with
carbonyl cyanide m-chlorophenyl hydrazone (CCCP) signiﬁ-
cantly diminished maximal respiration in the presence of the two
inhibitors compared to the untreated control. These ﬁndings
suggest an energy generation pathway common to both fatty acid
and glucose oxidation as the target of the compounds. Previous
Table 5. Pharmacokinetic Proﬁling of Compounds 1, 7, and 11
1 7 11
GAST MIC (μM) 0.3 (95 ng/mL) 0.4 (141 ng/mL) 0.8 (294 ng/mL)
7H9-ADC MIC (μM) 0.6 (190 ng/mL) 0.4 (141 ng/mL) 0.8 (294 ng/mL)
HepG2 IC50 (μM) >50 >50 >50
measured CHI-LogD 1.8 1.5 1.6
microsomal clearance (mL/min/g) mouse 2.3 mouse 1.4 mouse 4.8
human <0.5
MWa 317 353 367
cLogPa/cLogDa 2.3/2.3 2.3/2.3 2.7/2.7
TPSAa 75 75 75
PAMPA (nm/s) 83 64 65
kinetic solubility (μM)b 83 (free base) 111 (HCl salt) >250
C57 mouse PK at 3 iv and 10 po (mg/kg) free base HCl salt free base
Cmax (ng/mL) 748 399 1112
T1/2 (h) 1.5 1.3
AUC0−8h (ng·min/mL) 156 800 67 085 128 309
Clb (mL/min/kg) 23 39
Vdss (L/kg) 0.8 1
% F 46 29
PPB (% unbound) 14 13 21
aCalculated using StarDrop (http://www.optibrium.com). bKinetic aqueous solubility was measured using laser nephelometry of compounds in
2.5% DMSO.
Figure 3. Mercapto-quinazolinones deplete cellular ATP levels in MTb.
ATP was measured using the BacTiter Glo assay after 24 h of drug expo-
sure and expressed as a fraction of the drug-free vehicle control levels.
Figure 4. Mtb lacking the alternative type II NADH dehydrogenase
encoded by ndhA was more susceptible to compound 1. Colony-
forming units (CFU) after 7 days of treatment as compared to CFU at
start of drug treatment (inoculum). Unpaired t test comparison between
WT and ΔndhA at 0.5 μM compound 1: two-tailed P-value = 0.0023.
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studies21,36 have shown that MTb can rapidly reroute electron
ﬂux to overcome inhibition of cytochrome bc1−aa3, cytochrome bd,
or ATP synthase, resulting in enhanced respiration. Therefore,
we speculated that the target of compounds 1 and 7 was at the
point of entry into the electron transport chain (ETC), that is,
Complex 1 (NADH dehydrogenase) or Complex II (succinate
dehydrogenase). To test this prediction, ATP production was
measured inMTb inverted membrane vesicles (IMVs) in the pres-
ence of themercapto-quinazolinones (Figure 5C,D).Notably, ATP
production was signiﬁcantly inhibited when NADH was pro-
vided as electron donor but not when succinate was the source of
reducing equivalents, suggesting that the site of inhibition was
NADH dehydrogenase. The mechanism by which the com-
pounds interfere with NADH dehydrogenase function diﬀers
from clofazimine and the quinolinequinones, which have been
proposed to interfere with electron transport by activating
NDH-2 resulting in production of reactive oxygen species.18,20
To verify that NDH-2 was indeed the target for this class of
mercapto-quinazolinones, we expressed MTb NDH-2 (MtNdh)
encoded by the predicted essential ndh in E. coli as a recombinant
MBP-fusion protein and puriﬁed the protein to near homoge-
neity via amylose-resin aﬃnity chromatography and gel ﬁltration.
The recombinant enzyme was highly active with coenzyme Q2
(ubiquinone Q-2) and NADH as substrates, delivering steady-
state kinetic parameters similar to previously published results.37
Quinazolinones 1−3, 7, and 11were found to have submicromolar
IC50 values against theMtNdh (Figure 6). Compounds 1, 7, and 11
showed the highest potency, with IC50 values from 7 to 26 nM,
values 3-orders of magnitude lower than that for the previously
characterized NDH-2 inhibitor chlorpromazine (CPZ; 10−25 μM;
Figure 6)24 but superior to the quinolinyl pyrimidines discovered in
a target-based screening eﬀort against theMTbNDH-2.38No time-
dependent inhibition was observed for these compounds. The
mode of inhibition against MtNdh was further investigated using
Figure 5.Mercapto-quinazolinones target Complex I of theMTb ETC. At the times indicated by the dotted vertical lines, either glucose (A) or palmitate
(B) was added to MTb as carbon source (CS), followed by the mercapto-quinazolinones (Compound) and, last, the uncoupler CCCP to induce
maximal respiration. The mercapto-quinazolinones diminished MTb’s uncoupling capacity signiﬁcantly compared to that of the untreated (UT)
control. The oxygen consumption rate (OCR) is reported as a percentage of baseline values. Mercapto-quinazolinones inhibit ATP production in the
presence of NADH but not succinate. (C, D) ATP production in inverted membrane vesicles (IMVs) in the presence of NADH or succinate as electron
donors after 30 min (C) and over 60 min (D). P-values were calculated by one-way ANOVA using GraphPad Prism 7.02.
Figure 6. Inhibition of recombinant MBP-MtNdh by select
quinazolinones. Steady-state enzyme activity was measured by
monitoring absorbance changes at 340 nm due to NADH oxidation,
as described in the Experimental Section. NADH and Q2 were ﬁxed at
250 and 40 μM, respectively. Each data point is themean± SD of at least
3 independent measurements. Inset table shows calculated IC50 values.
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compound 1: double reciprocal plots of enzyme activity under
varying concentrations of 1 and either Q2 or NADH suggested
patterns indicative of a noncompetitive mode of inhibition with
both substrates (Ki values of 30−40 nM), although the eﬀect on
slopewas less evident when varyingQ2 (Figure 7). This is similar to
previous studies with a thiophenazine-based NDH-2 inhibitor39
and suggests that inhibition occurs through binding of the com-
pound at an allosteric site, independent of the main substrate
binding pockets.
In conclusion, the nonproton pumping type II NADH dehy-
drogenase (NDH-2) has been shown to play a critical role in the
respiratory metabolism of bacteria. The 2-mercapto-quinazoli-
none scaﬀold is a potent inhibitor of the mycobacterial NDH-2,
and although in this study MTb whole-cell SAR only obtained
limited improvement in potency, this information, together with
the recently disclosed structural information on the enzyme from
the bacterium Caldalkalibacillus thermarum,40 will aid in the future
rational structure-based development of new and improvedNDH-2
inhibitors. Critical for any structure-guided inhibitor design is an
understanding of the ligand-binding pocket of the NDH-2 pro-
tein. The low amino acid identity between the C. thermarum and
MTbNDH-2 proteins (30%) combined with the ﬁnding that this
inhibitor likely binds to an allosteric site with no allosteric ligand-
binding sites identiﬁed on the existing bacterial NDH-2 struc-
ture40 suggests that cocrystallization of the compound with the
MTb NDH-2 protein will be essential to facilitate rational drug
design. During revision of this paper, the SARof a similarmercapto-
quinazolinone scaﬀold41 was reported with a complementary paper
describing the importance of the mycobacterial type II NADH
dehydrogenase despite the nonessentiality of the individual ndh
and ndhA genes.42
■ EXPERIMENTAL SECTION
Chemistry Summary. All commercially available reagents,
solvents, and starting materials were purchased from Aldrich
Chemical Co. (UK). Where necessary, a Biotage FLASH 25+
column chromatography system was used to purify mixtures;
reagent-grade solvents used for chromatography were purchased
from Fisher Scientiﬁc (UK), and ﬂash column chromatography
silica cartridges were obtained from Biotage (UK). Analytical
thin-layer chromatography (TLC) was performed on precoated
TLC plates (layer 0.20 mm silica gel 60 with ﬂuorescent indicator
UV254, from Merck). Developed plates were air-dried and ana-
lyzed under a UV lamp (UV 254/365 nm). Microwave irra-
diation was conducted using a BIOTAGE INITIATOR unit. The
machine consists of a continuous focused microwave power deliv-
ery system with operator-selectable power output (0−400 W at
2.45 GHz). All 1H and 13C NMR spectra were recorded on a
Bruker ARX-500 spectrometer (500 and 300 MHz for 1H and
13C NMR, respectively). Chemical shifts (δ) are reported in
ppm relative to the residual solvent peak or internal standard
(tetramethylsilane), and coupling constants (J) are reported in
hertz (Hz). Data are reported as follows: chemical shift, multi-
plicity (br = broad, s = singlet, d = doublet, t = triplet, m = mul-
tiplet), and integration. LC−MS analyses were performed with
either anAgilentHPLC1100 series connected to aBrukerDaltonics
MicrOTOF or an Agilent Technologies 1200 series HPLC con-
nected to an Agilent Technologies 6130 quadrupole spectrom-
eter, where both instruments were connected to an Agilent diode
array detector. LC−MS chromatographic separations were con-
ducted with a Waters X bridge C18 column, 50 mm × 2.1 mm,
3.5 μm particle size; mobile phase of water/acetonitrile + 0.1%
HCOOHor water/acetonitrile + 0.1%NH3; linear gradient from
80:20 to 5:95 over 3.5 min and then held for 1.5 min; ﬂow rate of
0.5 mL·min−1. All assay compounds had a measured purity of
≥95% (by TIC and UV) as determined using this analytical
LC−MS system. High resolution electrospray measurements were
performed on a Bruker Daltonics MicrOTOF mass spectrometer.
General Method for the Preparation of Amide Coupling
(1, 4−11, 14−16, 19−27). To a solution of 2-((4-oxo-3,4-
dihydroquinazolin-2-yl)thio)acetic acid (1.0 equiv) in a 1:1 ratio of
acetonitrile (1.5 mL) and DMF (1.5 mL) were added EDC·HCl
(1.0 equiv), HOAT (1.2 equiv), or HATU (1.0 equiv) and pri-
mary/secondary amine (1.0 equiv), and the mixture was stirred
for 30 min; DIPEA (2.0 equiv) was added to the reaction mixture
and stirred at room temperature overnight. If a precipitate had
formed this was ﬁltered oﬀ, washed with acetonitrile, and air-
dried. If the reaction mixture had remained homogeneous, the
solution was puriﬁed directly by preparative HPLC under acidic
conditions, using 0.1% HCOOH in water/acetonitrile (5−95%)
gradient elution to aﬀord the product.
N-Cyclohexyl-2-((4-oxo-3,4-dihydroquinazolin-2-yl)thio)-
acetamide (1). To a solution of acid of 2-((4-oxo-3,4-
dihydroquinazolin-2-yl)thio)acetic acid (30) (500 mg, 2.1 mmol,
1.0 equiv) in 1:1 ratio of acetonitrile (1.5 mL) and DMF (1.5 mL)
were added EDC·HCl (1.2 equiv), HOAT (1.2 equiv), or HATU
(804 mg, 2.1 mmol, 1.0 equiv) in DCM (3 mL) and cyclo-
hexylamine (209 mg, 2.1 mmol, 1.0 equiv), and the mixture was
stirred for 30 min; DIPEA (0.73 mL, 2.1 mmol, 2.0 equiv) was
added to the reaction mixture and stirred at room temperature
Figure 7.Double-reciprocal plot of inhibition kinetics of MBP-MtNdh by 1. NADH (left) or Q2 (right) concentrations were varied, in the presence of
ﬁxed concentrations of 40 μMQ2 (A) or 250 μMNADH (B). Data points are the average of at least 3 independent measurements. Solid lines represent
best-ﬁt values of the data to the general Michaelis−Menten reversible inhibition equation, using nonlinear regression analysis.
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overnight. The reaction mixture was puriﬁed by preparative HPLC
under acidic conditions, using 0.1% HCOOH in water/acetonitrile
(5−95%) gradient elution to aﬀord a white solid ofN-cyclohexyl-2-
((4-oxo-3,4-dihydroquinazolin-2-yl)thio)acetamide as a white
powder (450 mg, 66% yield), C16H19N3O2S, MW 317.41;
1H NMR (500 MHz, DMSO) δ 12.66 (brs, 1H), 8.14 (d, J =
7.9 Hz, 1H), 8.04 (dd, J = 1.3, 7.9 Hz, 1H), 7.80−7.76 (m, 1H),
7.50 (d, J =7.9Hz, 1H), 7.45−7.41 (m, 1H), 3.92 (s, 2H), 3.59−3.51
(m, 1H), 1.76−1.64 (m, 4H), 1.55 (dd, J = 3.5, 9.1 Hz, 1H),
1.30−1.12 (m, 5H). LCMS m/z 318.12 [M + 1]+ 100%. HRMS
(m/z): [M + H]+ calcd for C16H20N3O2S, 318.1270; found,
318.1284.
N-Cycloheptyl-2-((4-oxo-3,4-dihydroquinazolin-2-yl)thio)-
acetamide (4).White powder (21mg, 23% yield), C17H21N3O2S,
MW 331.43; 1H NMR (500 MHz, DMSO) δ 12.65 (brs, 1H),
8.26 (d, J = 7.8 Hz, 1H), 8.02 (dd, J = 1.3, 7.9 Hz, 1H), 7.77−7.72
(m, 1H), 7.48−7.37 (m, 2H), 3.88 (s, 2H), 3.73 (ddd, J = 4.2, 8.6,
16.9 Hz, 1H), 1.60−1.34 (m, 12H). LCMSm/z 332.14 [M + 1]+
100%. HRMS (m/z): [M + H]+ calcd for C17H22N3O2S,
332.1427; found, 332.1439.
N-Cyclopentyl-2-((4-oxo-3,4-dihydroquinazolin-2-yl)thio)-
acetamide (5).White powder (39mg, 24% yield), C15H17N3O2S,
MW 303.38; 1H NMR (500 MHz, DMSO) δ 8.23 (d, J =
7.1 Hz, 1H), 8.04 (dd, J = 1.3, 8.0 Hz, 1H), 7.79−7.75 (m, 1H),
7.49 (d, J = 8.0 Hz, 1H), 7.45−7.41 (m, 1H), 4.03−3.98 (m, 1H),
3.91 (s, 2H), 1.82−1.76 (m, 2H), 1.67−1.62 (m, 2H), 1.53−1.36
(m, 4H). LCMS m/z 304.12 [M + H]+ 100%. HRMS (m/z):
[M + H]+ calcd for C15H18N3O2S, 304.1114; found, 304.1107.
N-Cyclobutyl-2-((4-oxo-3,4-dihydroquinazolin-2-yl)thio)-
acetamide (6).White powder (76mg, 66% yield), C14H15N3O2S,
MW 289.35; 1H NMR (400 MHz, DMSO) δ 12.67 (s, 1H), 8.54
(d, J = 7.7 Hz, 1H), 8.05−8.02 (m, 1H), 7.81−7.75 (m, 1H), 7.51
(d, J = 8.1 Hz, 1H), 7.43 (t, J = 7.5 Hz, 1H), 4.19 (dd, J = 8.1,
16.1 Hz, 1H), 3.91 (s, 2H), 2.20−2.10 (m, 2H), 1.97−1.85
(m, 2H), 1.67−1.57 (m, 2H). LCMS m/z 290.04 [M + H]+
100%. HRMS (m/z): [M + H]+ calcd for C14H16N3O2S,
290.0957; found, 290.0962.
N-(4,4-Diﬂuorocyclohexyl)-2-((4-oxo-3,4-dihydroquinazo-
lin-2-yl)thio)acetamide (7). To a solution of 2-((4-oxo-3,4-
dihydroquinazolin-2-yl)thio)acetic acid 30 (108 mg, 0.4 mmol,
1.0 equiv) inDCM(3mL)were addedHATU (160mg, 0.4mmol,
1.0 equiv) and 4,4-diﬂuorocyclohexan-1-amine (57 mg,
0.4 mmol, 1.0 equiv) and the mixture was stirred for 30 min;
DIPEA (0.074 mL, 0.4 mmol, 2.0 equiv) was added to the reac-
tion mixture and stirred at room temperature overnight. The
reaction mixture was puriﬁed by preparative HPLC under acidic
conditions, using 0.1% HCOOH in water/acetonitrile (5−95%)
gradient elution to aﬀord a white solid of N-(4,4-diﬂuorocyclo-
hexyl)-2-((4-oxo-3,4-dihydroquinazolin-2-yl)thio)acetamide as
a white powder 7 (115 mg, 75% yield), C16H17F2N3O2S, MW
353.39; 1H NMR (500MHz, DMSO) δ 12.64 (s, 1H), 8.39 (d, J =
6.9 Hz, 1H), 8.02 (dd, J = 1.2, 7.9 Hz, 1H), 7.77−7.72 (m, 1H),
7.46 (d, J = 7.9 Hz, 1H), 7.40 (t, J = 7.5 Hz, 1H), 3.90 (s, 2H),
3.77 (t, J = 4.0 Hz, 1H), 2.04−1.75 (m, 6H), 1.56−1.47 (m, 2H).
LCMS m/z 354.14 [M + H]+ 100%. HRMS (m/z): [M + H]+
calcd for C16H18F2N3O2S, 354.1082; found, 354.1091.
N-(4,4-Diﬂuorocyclohexyl)-2-((4-oxo-3,4-dihydroquinazo-
lin-2-yl)thio)acetamide HCl Salt Preparation (7). N-(4,4-
Diﬂuorocyclohexyl)-2-((4-oxo-3,4-dihydroquinazolin-2-yl)thio)-
acetamide (60 mg, 0.17 mmol, 1.0 equiv) in ethyl acetate (10 mL)
and ethanol (3mL) was heated up to 80 °C, until dissolved (90%).
The solution was cooled immediately, followed by the addition of
2 M HCl in diethyl ether (1 mL, 747 mg, 20.49 mmol, 120 equiv)
and stirred for a further 15 min, where white precipitates were
formed. The precipitate was ﬁltered and dried to aﬀord the
N-(4,4-diﬂuorocyclohexyl)-2-((4-oxo-3,4-dihydroquinazolin-2-yl)-
thio)acetamide HCl salt (50 mg, 75% yield), C16H17F2N3O2S·HCl,
MW 389.85; 1H NMR (500 MHz, DMSO) δ 8.32 (d, J =
7.6 Hz, 1H), 8.04 (dd, J = 1.2, 7.9 Hz, 1H), 7.80−7.76 (m, 1H),
7.49 (d, J = 7.8 Hz, 1H), 7.45−7.41 (m, 1H), 3.95 (s, 2H),
2.52−2.50 (m, 1H), 2.05−1.99 (m, 2H), 1.97−1.76 (m, 4H),
1.57−1.48 (m, 2H). LCMSm/z 354.14 [M + H]+ 100%. HRMS
(m/z): [M + H]+ calcd for C16H18F2N3O2S, 354.1082; found,
354.1091.
N-(2,2-Diﬂuorocyclohexyl)-2-((4-oxo-3,4-dihydroquinazo-
lin-2-yl)thio)acetamide (8). White powder (93 mg, 62% yield),
C16H17F2N3O3S2, MW 353.39;
1H NMR (500 MHz, DMSO) δ
12.64 (s, 1H), 8.46 (d, J = 9.0 Hz, 1H), 8.04 (d, J = 7.9 Hz, 1H),
7.79−7.75 (m, 1H), 7.50 (d, J = 8.2 Hz, 1H), 7.43 (dd, J =
7.5 Hz, 1H), 4.03−4.01 (m, 3H), 2.08−2.03 (m, 1H), 1.86−1.63
(m, 4H), 1.49−1.38 (m, 3H). LCMS m/z 354.10 [M + H]+
100%. HRMS (m/z): [M + H]+ calcd for C16H18F2N3O3S2,
354.1082; found, 354.1094.
N-(3,3-Diﬂuorocyclohexyl)-2-((4-oxo-3,4-dihydroquinazo-
lin-2-yl)thio)acetamide (9). White powder (83 mg, 55% yield),
C16H17F2N3O3S2, MW 353.39;
1H NMR (500 MHz, DMSO) δ
12.61 (brs, 1H), 8.31 (d, J = 7.9 Hz, 1H), 8.04 (dd, J = 1.3, 7.9 Hz,
1H), 7.80−7.76 (m, 1H), 7.50 (d, J = 8.2 Hz, 1H), 7.43 (t, J =
7.5 Hz, 1H), 3.94 (s, 2H), 3.91−3.75 (m, 1H), 2.21−2.15
(m, 1H), 1.98−1.95 (m, 1H), 1.81−1.68 (m, 4H), 1.45−1.24
(m, 2H). LCMS m/z 354.10 [M + H]+ 100%. HRMS (m/z):
[M +H]+ calcd for C16H18F2N3O3S2, 354.1082; found, 354.1095.
N-(Cyclohexylmethyl)-2-((4-oxo-3,4-dihydroquinazolin-2-
yl)thio)acetamide (10). White powder (34 mg, 25% yield),
C17H21N3O2S, MW 331.43;
1H NMR (500 MHz, DMSO) δ
12.64 (s, 1H), 8.16 (s, 1H), 8.05−8.02 (m, 1H), 7.79−7.75
(m, 1H), 7.50 (dd, J = 3.1, 8.1 Hz, 1H), 7.44−7.40 (m, 1H), 3.93
(d, J = 2.5 Hz, 2H), 2.95−2.92 (m, 2H), 1.67−1.58 (m, 5H),
1.38−1.34 (m, 1H), 1.12−1.07 (m, 3H), 0.87−0.79 (m, 2H).
LCMS m/z 332.21 [M + H]+ 100%. HRMS (m/z): [M + H]+
calcd for C17H22N3O2S, 332.1427; found, 332.1431.
N-((4,4-Diﬂuorocyclohexyl)methyl)-2-((4-oxo-3,4-dihydro-
quinazolin-2-yl)thio)acetamide (11). White powder (120 mg,
77% yield), C17H19N3F2O2S, MW 367.41;
1H NMR (500 MHz,
DMSO) δ 12.64 (s, 1H), 8.27 (t, J = 5.8 Hz, 1H), 8.04 (dd, J =
1.3, 7.9 Hz, 1H), 7.80−7.76 (m, 1H), 7.50 (d, J = 8.0 Hz, 1H),
7.45−7.42 (m, 1H), 3.95 (s, 2H), 3.02 (t, J = 6.4 Hz, 2H),
1.96−1.87 (m, 2H), 1.74−1.52 (m, 5H), 1.17−1.08 (m, 2H).
LCMS m/z 368.01 [M + H]+ 100%. HRMS (m/z): [M + H]+
calcd for C17H20N3F2O2S, 368.1238; found, 368.1255.
N-Cyclohexyl-N-methyl-2-((4-oxo-3,4-dihydroquinazolin-
2-yl)thio)acetamide (14). White powder (35 mg, 25% yield),
C17H21N3O2S, MW 331.43;
1H NMR (500 MHz, DMSO) δ
12.60 (brs, 1H), 8.04 (dd, J = 1.6, 7.9 Hz, 1H), 7.80−7.74
(m, 1H), 7.49−7.40 (m, 2H), 4.34 (s, 1H), 4.23 (s, 1H),
3.80−3.76 (m, 1H), 3.01 (s, 2H), 2.74 (s, 1H), 1.76 (t, J =
12.0 Hz, 3H), 1.62−1.52 (m, 2H), 1.52−1.43 (m, 2H),
1.38−1.23 (m, 2H), 1.15−1.05 (m, 1H). LCMS m/z 332.15
[M + H]+. HRMS (m/z): [M + H]+ calcd for C17H22N3O2S,
332.1427; found, 332.1440.
2-((4-Oxo-3,4-dihydroquinazolin-2-yl)thio)propanoic Acid
(56). To a solution of 2-thioxo-2,3-dihydroquinazolin-
4(1H)-one 29 (500 mg, 2.8 mmol, 1.0 equiv) were added
2-bromopropanoic acid (557 mg, 3.6 mmol, 1.3 equiv) and
triethylamine (2.3 mL, 16.8 mmol, 6.0 equiv) in DMF (5 mL),
and the mixture was stirred for 12 h at 75 °C. Once the reaction
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has completed, it was poured onto crushed ice and acidiﬁed with
1 N HCl, where the product precipitated out of the solution.
The precipitate was ﬁltered and dried to yield 2-((4-oxo-3,4-
dihydroquinazolin-2-yl)thio)propanoic acid 56 (548mg, 78% yield),
C11H10N2O3S, MW 250.27;
1H NMR (500 MHz, DMSO) δ
12.66 (s, 1H), 8.04 (q, J = 3.10 Hz, 1H), 7.70 (m, 1H), 7.50 (d, J =
8.00 Hz, 1H), 7.44 (m, 1H), 4.57 (q, J = 7.3 Hz, 2H), 1.55 (d, J =
7.30 Hz, 3H). LCMS m/z 251.00 [M + H]+ 100%.
N-Cyclohexyl-2-((4-oxo-3,4-dihydroquinazolin-2-yl)thio)-
propanamide (15). White powder (45 mg, 35% yield),
C17H21N3O2S, MW 331.43;
1H NMR (500 MHz, DMSO) δ
12.59 (brs, 1H), 8.17 (d, J = 7.7Hz, 1H), 8.04 (dd, J = 1.4, 7.9 Hz,
1H), 7.81−7.77 (m, 1H), 7.53 (d, J = 8.2 Hz, 1H), 7.45−7.42
(m, 1H), 4.54 (q, J = 7.0 Hz, 1H), 3.56−3.48 (m, 1H), 1.76−1.61
(m, 4H), 1.53−1.50 (m, 4H), 1.29−1.10 (m, 5H). LCMS m/z
332.10 [M + H]+ 100%. HRMS (m/z): [M + H]+ calcd for
C17H22N3O2S, 332.1427; found, 332.1432.
N-Cyclohexyl-N-methyl-2-((4-oxo-3,4-dihydroquinazolin-
2-yl)thio)propanamide (16).White powder (40 mg, 29% yield),
C18H23N3O2S, MW 345.46;
1H NMR (500 MHz, DMSO) δ
12.60 (brs, 1H), 8.07−8.02 (m, 1H), 7.82−7.75 (m, 1H),
7.50−7.41 (m, 2H), 4.24−4.18 (m, 1H), 3.05 (s, 2H), 2.75 (s, 1H),
1.80−1.70 (m, 3H), 1.64−1.54 (m, 1H), 1.54−1.47 (m, 6H),
1.36−1.20 (m, 2H), 1.14−1.02 (m, 2H). LCMS m/z 346.10
[M + H]+ 100%. HRMS (m/z): [M + H]+ calcd for
C18H24N3O2S, 346.1584; found, 346.1608.
N-Cyclohexylglycine (53). Cyclohexylamine 51 (100 mg,
1.0 mmol, 1.0 equiv) and ethyl 2-hydroxyacetate 52 (104.9 mg,
1.0 mmol, 61.0 equiv) were stirred neat in a round-bottom ﬂask
for 12 h. The solvent of the crude mixture was evaporated com-
pletely, and the residue was puriﬁed via ﬂash column chro-
matography eluting with 10% DCM in methanol to aﬀord
N-Cyclohexylglycine 53 (100 mg, 63% yield), C8H15NO2, MW
157.21; 1H NMR (500 MHz, DMSO) δ 6.34 (brs, 1H),
4.05−4.04 (m, 2H), 3.82−3.77 (m, 1H), 3.77−3.69 (m, 1H),
1.86−1.83 (q, J = 5.28 Hz, 2H), 1.67−1.63 (m, 2H), 1.57−1.53
(m, 1H), 1.35−1.26 (m, 2H), 1.15−1.07 (m, 3H). LCMS m/z
158.21 [M + H]+ 100%.
2-(Methylthio)quinazolin-4(3H)-one (54). A solution of
iodomethane (398 mg, 2.8 mmol, 1.0 equiv) in methanol (8 mL)
was added slowly to a closed vessel containing a solution of 2-thioxo-
2,3-dihydroquinazolin-4(1H)-one 29 (500mg, 2.8mmol, 1.0 equiv)
in 1% aqueous NaOH (8 mL) under N2 atmosphere and stirred
for 1 h at room temperature. The reaction mixture was then cooled
to 0 °C, and the pHwas adjusted to 7 with an aqueous solution of
1 N HCl. The solvent was removed under reduced pressure, and
the solid was ﬁltered, washed with water/methanol, and dried to
aﬀord 2-(methylthio)quinazolin-4(3H)-one 54 (532 mg,
98% yield), C9H8N2OS, MW 192.24;
1H NMR (500 MHz,
DMSO) δ 12.62 (s, 1H), 8.09 (q, J = 3.13 Hz, 1H), 7.81 (m, 1H),
7.59 (d, J = 8.10 Hz, 1H), 7.47 (m, 1H), 2.63 (s, 3H). LCMSm/z
193.18 [M + H]+ 100%.
N-Cyclohexyl-2-((4-oxo-3,4-dihydroquinazolin-2-yl)-
amino)acetamide (17). 2-Amino-N-cyclohexyl-acetamide 55
(40.63 mg, 0.26 mmol, 1.0 equiv), 2-(methylthio)quinazolin-
4(3H)-one 54 (50 mg, 0.26 mmol, 1.0 equiv) were suspended in
ethyl acetate (2 mL) in a sealed microwave vial and irradiated
(0−400W at 2.65 GHz) at 140 °C for 2 h. Upon completion, the
reaction was ﬁltered and the ﬁltrate was extracted with diethyl
ether to aﬀord N-cyclohexyl-2-((4-oxo-3,4-dihydroquinazolin-2-
yl)amino)acetamide as a white powder 17 (4.4 mg, 4.4% yield),
C16H20N4O2, MW 300.36;
1H NMR (500 MHz, DMSO) δ 8.10
(d, J = 7.7 Hz, 1H), 7.58−7.56 (m, 1H), 7.33 (d, J = 8.7 Hz, 1H),
7.22−7.18 (m, 1H), 3.95 (s, 2H), 1.76−1.66 (m, 4H), 1.56−1.53
(m, 1H), 1.31−1.07 (m, 6H). LCMSm/z 301.0 [M +H]+ 100%.
HRMS (m/z): [M + H]+ calcd for C16H21N4O2, 301.1659;
found, 301.1665.
N-Cyclohexyl-2-((4-oxo-3,4-dihydroquinazolin-2-yl)oxy)-
acetamide (18). 2-(Methylthio)quinazolin-4(3H)-one 54
(50 mg, 0.26 mmol, 1.0 equiv) and N-cyclohexylglycine 53
(21.7 mg, 0.12 mmol, 1.0 equiv) were dissolved in THF (2 mL)
and heated to 80 °C. Upon reaction completion, the crude prod-
uct was directly puriﬁed via prep-HPLCGilson puriﬁcation using
0.1% ammonia in water/acetonitrile 5−95% gradient elution to
aﬀord the product as a white powder 18 (10 mg, 24% yield),
C16H19N3O3, MW 301.34;
1HNMR (500MHz, DMSO) δ 12.36
(brs, 1H), 8.03 (d, J = 7.7 Hz, 1H), 7.9 (d, 1H), 7.73 (d, J =
8.7 Hz, 1H), 7.40−7.33 (m, 1H), 3.77 (s, 2H), 3.60−3.56
(m, 1H), 1.76−1.66 (m, 4H), 1.57−1.53 (m, 1H), 1.31−1.10
(m, 6H). LCMS m/z 302.1 [M + H]+ 100%. HRMS (m/z):
[M + H]+ calcd for C16H20N3O32, 302.1499; found, 302.1487.
N-Cyclohexyl-3-(4-oxo-3,4-dihydroquinazolin-2-yl)-
propanamide (19). White powder (110 mg, 80% yield),
C17H21N3O2, MW 299.37;
1H NMR (500 MHz, DMSO) δ
12.18 (s, 1H), 8.08 (dd, J = 1.3, 7.9 Hz, 1H), 7.85−7.76 (m, 2H),
7.56 (d, J = 8.0 Hz, 1H), 7.48−7.45 (m, 1H), 3.55−3.48 (m, 1H),
2.83 (t, J = 7.4 Hz, 2H), 2.58 (t, J = 7.4 Hz, 2H), 1.73−1.64
(m, 4H), 1.55−1.52 (m, 1H), 1.28−1.09 (m, 5H). LCMS m/z
300.10 [M + H]+ 100%. HRMS (m/z): [M + H]+ calcd for
C17H22N3O2, 300.1707; found, 300.1721.
2-((3-Methyl-4-oxo-3,4-dihydroquinazolin-2-yl)thio)acetic
Acid (50). 2-Mercapto-3-methylquinazolin-4(3H)-one 49
(220 mg, 1.14 mmol, 1.0 equiv), 2-bromoacetic acid (206 mg,
1.48 mmol, 1.3 equiv), and triethylamine (0.95 mL, 6.8 mmol,
6.0 equiv) were stirred in DMF (5 mL) for 12 h at 75 °C. Upon
reaction completion, the reactionmixture was poured onto crushed
ice and acidiﬁed with 1 N HCl. The precipitate formed was
collected and dried to aﬀord the product 2-((3-methyl-4-oxo-3,4-
dihydroquinazolin-2-yl)thio)acetic acid 50 (250 mg, 87% yield),
as awhite powder, C11H10N2O3S,MW250.27;
1HNMR(500MHz,
DMSO) δ 12.89 (s, 1H), 8.08 (q, J = 3.05 Hz, 1H), 7.79 (m, 1H),
7.46 (m, 2H), 4.11 (s, 2H), 3.55 (s, 3H). LCMS m/z 251.04
[M + H]+ 100%.
N-Cyclohexyl-2-((3-methyl-4-oxo-3,4-dihydroquinazolin-
2-yl)thio)acetamide (20). White powder (20 mg, 15% yield),
C17H21N3O2S, MW 331.42;
1HNMR (500MHz, DMSO) δ 8.15
(d, J = 7.9 Hz, 1H), 8.08 (d, J = 7.9 Hz, 1H), 7.82−7.78 (m, 1H),
7.52 (d, J = 8.2 Hz, 1H), 7.47−7.43 (m, 1H), 3.98 (s, 2H), 3.54
(s, 4H), 1.76−1.65 (m, 4H), 1.55 (d, J = 12.8 Hz, 1H), 1.28−1.11
(m, 5H). LCMS m/z 332.15 [M + H]+ 100%. HRMS (m/z):
[M + H]+ calcd for C17H22N3O2S, 332.1427; found, 332.1436.
2-(Quinazolin-2-ylthio)acetic Acid (44). 2-Chloroquinazo-
line 43 (0.2 g, 1.22 mmol) and sodium thioglycolic acid 39b
(1 equiv) were dissolved in DMF, and triethylamine (6.0 equiv)
was added. The reaction mixture was heated to 100 °C overnight.
The resulting precipitate was ﬁltered and used without any fur-
ther puriﬁcation to aﬀord the product 2-(quinazolin-2-ylthio)-
acetic acid 44 (0.153 g, 57% yield) as a white powder, C10H8N2O2S,
MW 220.25; 1H NMR (500 MHz, DMSO) δ 9.41 (d, J = 1.5 Hz,
1H), 8.09 (m, 1H), 7.95−7.93 (m, 1H), 7.79−7.77 (m, 1H),
7.66−7.61 (m, 1H), 4.05 (s, 2H). LCMS m/z 221.1 [M + H]+
100%.
N-Cyclohexyl-2-(quinazolin-2-ylthio)acetamide (21).White
powder (21mg, 10% yield), C16H19N3OS,MW301.41;
1HNMR
(300 MHz, DMSO) δ 9.36 (m, 1H), 8.05−8.0 (m, 2H),
7.79−7.76 (m, 1H), 3.95 (s, 2H), 3.52−3.48 (m, 1H), 2.49−2.48
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(m, 2H), 1.72−1.32 (m, 5H), 1.25−1.21 (m, 3H). LCMS m/z
302.1 [M + H]+ 100%.
2-((4-Aminoquinazolin-2-yl)thio)acetic Acid (46). 2-Chlor-
oquinazolin-4-amine 45 (0.2 g, 1.11 mmol, 1.0 equiv), sodium
thioglycolic acid 39b (0.103 g, 1.11 mmol, 1.0 equiv), and
triethylaminewere dissolved inDMF (2mL) (0.93mL, 6.68mmol,
6.0 equiv). The reaction mixture was heated to 100 °C overnight.
The resulting precipitate was ﬁltered to aﬀord a white powder
(0.2 g, 76% yield) and used without further puriﬁcation. LCMS
(ESI) m/z 236.1 [M + H]+
2-((4-Aminoquinazolin-2-yl)thio)-N-cyclohexylacetamide
(22). White powder (21 mg, 10% yield), C16H20N4OS, MW
316.42; 1H NMR (300 MHz, DMSO) δ 8.13 (dd, J = 3.0, 6.0 Hz,
1H), 7.97 (d, J = 6 Hz, 1H), 7.87 (brs, 2H), 7.77−7.69 (m, 1H),
7.51−7.49 (m, 1H), 7.38−7.34 (m, 1H), 3.75 (s, 2H), 3.55−3.45
(m, 1H), 1.76−1.47 (m, 5H), 1.23−1.09 (m, 5H). LCMS m/z
317.1 [M + H]+ 100%.
2-((4-Oxo-3,4,5,6,7,8-hexahydroquinazolin-2-yl)thio)-
acetic Acid (40). 2-Sulfanyl-5,6,7,8-tetrahydro-4-quinazolinol 38
(0.1 g, 5.49mmol, 1.0 equiv), chloroacetic acid 39a (1.3 equiv), and
triethylamine (6 equiv) were stirred in DMF at room temperature
overnight. Once the reaction was complete, the reaction mixture
was poured over crushed ice and acidiﬁed with 1 N HCl. The
white precipitate was collected by ﬁltration and washed with water
to aﬀord the product as a white powder (750 mg, 58% yield) which
was used without further puriﬁcation, C10H12N2O3S, MW 240.28;
1H NMR (300 MHz, DMSO) δ 12.59 (brs, 1H), 3.93 (s, 2H),
2.45 (t, J = 3.0 Hz, 2H), 2.29 (t, J = 3.0 Hz, 2H), 1.70−1.63
(m, 4H). LCMS (ESI) m/z 239.1 [M − H]+ 100%.
N-Cyclohexyl-2-((4-oxo-3,4,5,6,7,8-hexahydroquinazolin-
2-yl)thio)acetamide (23). White powder (43 mg, 17% yield),
C16H23N3O2S, MW 321.44;
1H NMR (300 MHz, DMSO) δ
12.47 (brs, 1H), 8.00 (brs, 1H), 3.80 (s, 2H), 3.58−3.49 (m, 1H),
2.47 (t, J = 3.0 Hz, 2H), 2.31 (t, J = 3.0 Hz, 2H), 1.75−1.54
(m, 9H), 1.29−1.13 (m, 5H). LCMSm/z 320.1 [M−H]+ 100%.
2-((4-Oxo-4,5,6,7-tetrahydro-3H-cyclopenta[d]pyrimidin-
2-yl)thio)acetic acid (42). 2-Thioxo-1,2,3,5,6,7-hexahydro-4H-
cyclopenta[d]pyrimidin-4-one 41 (1.0 g, 5.94 mmol, 1.0 equiv),
chloroacetic acid 39a (1.3 equiv), and triethylamine (6 equiv)
were stirred in DMF (2 mL) at room temperature overnight. Once
the reaction was complete, it was poured over crushed ice and
acidiﬁed with 1 N HCl. The white precipitate was collected by
ﬁltration and washed with water to aﬀord the product as a white
powder (800 mg, 59% yield), which was used without further
puriﬁcation, C9H10N2O3S, MW 226.05;
1H NMR (300 MHz,
DMSO) δ 12.65 (brs, 1H), 3.96 (s, 2H), 2.71 (t, J = 3.0 Hz, 2H),
2.58 (t, J = 3.0 Hz, 2H), 1.97−1.93 (m, 2H). LCMS m/z 227.1
[M + H]+ 100%.
N-Cyclohexyl-2-((4-oxo-4,5,6,7-tetrahydro-3H-cyclopenta-
[d]pyrimidin-2-yl)thio)acetamide(24). White powder (59 mg,
22% yield), C15H23N3O2S, MW 307.41;
1H NMR (300 MHz,
DMSO) δ 12.59 (brs, 1H), 8.03 (s, 1H), 3.84 (s, 2H), 3.58−3.49
(m, 1H), 2.71 (t, J = 3.0 Hz, 2H), 2.60 (t, J = 3.0 Hz, 2H),
2.0−1.92 (m, 2H), 1.75−1.52 (m, 5H), 1.29−1.16 (m, 5H).
LCMS (ESI) m/z 308.1 [M + H]+ 100%.
2-((4,5-Dimethyl-6-oxo-1,6-dihydropyrimidin-2-yl)thio)-
acetic Acid (48). 5,6-Dimethyl-2-thiouracil 47 (0.5 g, 3.20 mmol),
chloroacetic acid 39a (0.39 g, 4.16 mmol), and triethylamine
(2.62 mL, 1.94 mmol) were stirred in DMF (2 mL) at room tem-
perature overnight. Once the reaction was complete, it was
poured over crushed ice and acidiﬁed with 1 N HCl. The white
precipitate was collected by ﬁltration and washed with water to
aﬀord the product as a white powder (0.36 g, 54% yield) which
was used without further puriﬁcation, C8H10N2O3S, MW 214.24;
1H NMR (300 MHz, DMSO) δ 12.56 (brs, 1H), 3.89 (s, 2H),
2.14 (s, 3H), 1.85 (s, 3H). LCMS (ESI) m/z 213.1 [M − H];
HPLC purity 98%.
N-Cyclohexyl-2-((4,5-dimethyl-6-oxo-1,6-dihydropyrimi-
din-2-yl)thio)acetamide (25).White powder (0.047 g, 17% yield),
C14H21N3O2S, MW 295.40;
1H NMR (400 MHz, DMSO-d6) δ
7.99 (dd, J = 20.3, 8.1 Hz, 1H), 3.80 (s, 2H), 3.11−2.97 (m, 1H),
2.20 (s, 3H), 1.89 (s, 3H), 1.78−1.64 (m, 5H), 1.33−1.12
(m, 5H). LCMS (ESI) m/z 296.1 [M + H]+ 100%.
6-Fluoro-2-thioxo-2,3-dihydroquinazolin-4(1H)-one (33).
2-Amino-5-ﬂuorobenzoic acid 32 (1 g, 6.5 mmol, 1.0 equiv)
and thiourea (2.1 g, 25.8 mmol, 6.0 equiv) were heated neat in a
round-bottom ﬂask to 180 °C for 3 h with stirring. The reaction
was cooled, and 25mLofwater was added. After stirring for 10min,
the formed precipitate was ﬁltered oﬀ, washed with cold water, and
dried to aﬀord 6-ﬂuoro-2-thioxo-2,3-dihydroquinazolin-4(1H)-one
33 (0.45 g, 35.9% yield) as a yellow powder, C8H5FN2OS, MW
196.2; 1H NMR (500 MHz, DMSO) δ 9.72 (s, 1H), 7.51−7.39
(m, J = 8.5 Hz, 1H), 7.37−7.30 (m, J = 8.6 Hz, 1H), 7.19−7.16
(m, J = 8.85 Hz, 1H). LCMS m/z 197.78 [M + H]+ 100%.
2-((6-Fluoro-4-oxo-3,4-dihydroquinazolin-2-yl)thio)acetic
Acid (34). 6-Fluoro-2-thioxo-2,3-dihydroquinazolin-4(1H)-
one 33 (414 mg, 2.1 mmol, 1.0 equiv), 2-bromoacetic acid
(586.39 mg, 4.2 mmol, 2.0 equiv), and triethylamine (1.76 mL,
12.6 mmol, 6.0 equiv) were stirred in DMF (5 mL) at 75 °C for
12 h. Upon reaction completion, the reaction mixture was poured
over crushed ice and acidiﬁed with 1 N HCl. The precipitate was
ﬁltered and dried to aﬀord 2-((6-ﬂuoro-4-oxo-3,4-dihydroqui-
nazolin-2-yl)thio)acetic acid 34 (150 mg, 27.9% yield),
C10H7FN2O3S, MW 254.24;
1H NMR (500 MHz, DMSO) δ
12.88 (s, 1H), 7.72 (q, J = 3.87 Hz, 1H), 7.65 (m, 1H), 7.54 (q, J =
4.62 Hz, 1H), 4.03 (s, 2H). LCMS m/z 254.10 [M + H]+ 100%.
N-(4,4-Diﬂuorocyclohexyl)-2-((6-ﬂuoro-4-oxo-3,4-dihydro-
quinazolin-2-yl)thio)acetamide (26). To a solution of 2-((6-
ﬂuoro-4-oxo-3,4-dihydroquinazolin-2-yl)thio)acetic acid 34
(100 mg, 0.39 mmol, 1.0 equiv) in a 1:1 ratio of acetonitrile
(1.5 mL) and DMF (1.5 mL) were added EDC·HCl (90 mg,
0.74 mmol, 1.2 equiv), HOAT (64 mg, 0.47 mmol, 1.2 equiv), and
4,4-diﬂuorocyclohexan-1-amine (67 mg, 0.39 mmol, 1.0 equiv),
and the mixture was stirred for 30 min. DIPEA (0.13 mL,
0.78 mmol, 2.0 equiv) was added, and the resulting mixture was
stirred at room temperature overnight. The crude mixture was
puriﬁed by preparative HPLC under acidic conditions, using 0.1%
HCOOH in water/acetonitrile (5−95%) gradient elution to aﬀord
N-(4,4-diﬂuorocyclohexyl)-2-((6-ﬂuoro-4-oxo-3,4-dihydroquina-
zolin-2-yl)thio)acetamide as a white powder 26 (12 mg,
8.2% yield), C16H16N3F3O2S, MW 371.86;
1H NMR (500 MHz,
DMSO) δ 12.76 (brs, 1H), 8.39−8.36 (m, 1H), 7.71−7.60
(m, 2H), 7.52 (dd, J = 5.0, 8.9 Hz, 1H), 3.88 (s, 2H), 3.77 (d, J =
8.5 Hz, 1H), 2.08−1.77 (m, 6H), 1.55−1.47 (m, 2H). LCMS
m/z 372.3 [M + H]+ 100%. HRMS (m/z): [M + H]+ calcd for
C16H17N3F3O2S, 372.0988; found, 372.0987.
2-Thioxo-2,3-dihydropyrido[3,4-d]pyrimidin-4(1H)-one
(36). 2-Aminopyridine-4-carboxylic acid 35 (1 g, 7.2 mmol,
1.0 equiv) and thiourea (2.8 g, 36.2 mmol, 5.0 equiv) were heated
neat in a round-bottom ﬂask to 180 °C for 3 h with stirring. The
reaction was cooled, and 25 mL of water was added. After stirring
for 10 min, the formed precipitate was ﬁltered oﬀ, washed with
cold water, and dried to aﬀord 2-thioxo-2,3-dihydropyrido[3,4-
d]pyrimidin-4(1H)-one 36 (1.11 g, 85% yield) as a yellow pow-
der, C7H5FN2OS, MW 179.2;
1H NMR (500 MHz, DMSO) δ
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12.89 (brs, 1H), 12.70 (brs, 1H), 8.73 (s, 1H), 8.49 (d, J = 4.85 Hz,
1H), 7.79 (d, J = 0.80 Hz, 1H). LCMSm/z 180.11 [M +H]+ 100%.
2-((4-Oxo-3,4-dihydropyrido[3,4-d]pyrimidin-2-yl)thio)-
acetic Acid (37). 2-Thioxo-2,3-dihydropyrido[3,4-d]pyrimidin-
4(1H)-one 36 (500mg, 2.79 mmol, 1.0 equiv), 2-bromoacetic acid
(775.39 mg, 5.5 mmol, 2.0 equiv), and triethylamine (2.33 mL,
16.7 mmol, 6.0 equiv) were stirred in DMF (5 mL) at 75 °C for
12 h. Upon reaction completion, the reaction mixture was poured
over crushed ice and acidiﬁed with 1 N HCl, and the precipitate
was collected and dried to aﬀord 2-((4-oxo-3,4-dihydropyrido-
[3,4-d]pyrimidin-2-yl)thio)acetic acid 37 (600 mg, 90.6% yield),
C9H7N3O3S, MW 237.24;
1H NMR (500 MHz, DMSO) δ 12.89
(s, 1H), 8.85 (d, J = 0.65 Hz, 1H), 8.57 (d, J = 5.00 Hz, 1H), 7.88
(d, J = 0.80 Hz, 1H), 4.08 (s, 2H). LCMS m/z 238.15 [M + H]+
100%.
N-(4,4-Diﬂuorocyclohexyl)-2-((4-oxo-3,4-dihydropyrido-
[3,4-d]pyrimidin-2-yl)thio)acetamide (27). White powder
(64 mg, 42% yield), C15H16N4O2F2S, MW 354.38;
1H NMR
(500 MHz, DMSO) δ 13.02 (s, 1H), 8.86 (s, 1H), 8.57 (d, J =
5.2 Hz, 1H), 8.29 (d, J = 7.4 Hz, 1H), 7.87 (d, J = 5.0 Hz, 1H),
3.98 (s, 2H), 3.31 (s, 1H), 2.09−1.99 (m, 2H), 1.98−1.86
(m, 2H), 1.86−1.77 (m, 2H), 1.58−1.48 (m, 2H). LCMS m/z
355.22 [M + H]+ 100%. HRMS (m/z): [M + H]+ calcd for
C15H17N4O2F2S, 355.1034; found, 355.1033.
Intrinsic Clearance (Cli) Experiments. Test compound
(0.5 μM) was incubated with female CD1 mouse liver micro-
somes (Xenotech LLC; 0.5 mg/mL, 50 mM potassium phos-
phate buﬀer, pH 7.4), and the reaction started with addition of
excess NADPH (8 mg/mL, 50 mM potassium phosphate buﬀer,
pH 7.4). Immediately, at time zero, and then at 3, 6, 9, 15, and
30 min, an aliquot (50 μL) of the incubation mixture was removed
and mixed with acetonitrile (100 μL) to stop the reaction. Inter-
nal standard was added to all samples; the samples were centrif-
uged to sediment precipitated protein, and the plates were then
sealed prior to UPLC-MS/MS analysis using a Quattro Premier
XE (Waters Corporation, USA). XLﬁt (IDBS, UK) was used to
calculate the exponential decay and consequently the rate con-
stant (k) from the ratio of peak area of test compound to internal
standard at each time point. The rate of intrinsic clearance (Cli)
of each test compound was then calculated using the following
calculation.
= × ×k VCLi (mL/min/g liver) microsomal protein yield
where V (mL/mg protein) is the incubation volume/mg protein
added and microsomal protein yield is taken as 52.5 mg protein/g
liver. Verapamil (0.5 μM) was used as a positive control to con-
ﬁrm acceptable assay performance.
Aqueous Solubility. The aqueous solubility of the test com-
pounds was measured using laser nephelometry. Compounds
were subject to serial dilution from 10 to 0.5 mM in DMSO. An
aliquot was then mixed with Milli-Q water to obtain an aqueous
dilution plate with a ﬁnal concentration range of 250−12 μM,
with a ﬁnal DMSO concentration of 2.5%. Triplicate aliquots
were transferred to a ﬂat bottomed polystyrene plate which was
immediately read on the NEPHELOstar (BMG Lab Technolo-
gies). The amount of laser scatter caused by insoluble particulates
(relative nephelometry units, RNU)was plotted against compound
concentration using a segmental regression ﬁt, with the point of
inﬂection being quoted as the compounds aqueous solubility (μM).
CHI LogD Determination. The chromatographic hydro-
phobicity index (CHI) was determined according the method
previously described.43,44 Brieﬂy, test compounds were prepared
as 0.5 mM solutions in 50:50 acetonitrile/water and analyzed by
reversed-phase HPLC-UV (wavelength 254 nm) using a Phenom-
enex Luna C18 100 Å, 150 × 4.6 mm, 5 μm column with a gradient
of aqueous phase (50 mM ammonium acetate (pH 7.4)) and
mobile phase (acetonitrile). By plotting the retention time of a
set of reference compounds against known CHI values, the CHI
value of test compounds was calculated according to their
retention time.
Plasma Protein Binding Experiments. In brief, a 96-well
equilibrium dialysis apparatus was used to determine the free
fraction in plasma for each compound (HT Dialysis LLC, Gales
Ferry, CT). Membranes (12−14 kDaA cutoﬀ) were conditioned
in deionized water for 60 min, followed by conditioning in 80:20
deionized water/ethanol overnight and then rinsed in water and
isotonic buﬀer before use. Mouse plasma from appropriate spe-
cies was removed from the freezer and allowed to thaw on the day
of experiment. Thawed plasma was then centrifuged (Allegra
X12-R, Beckman Coulter, USA) and spiked with test compound
(ﬁnal concentration 10 μg/mL), and 150 μL aliquots (n = 3 rep-
licate determinations) were loaded into the 96-well equilibrium
dialysis plate. Dialysis against isotonic buﬀer (150 μL) was
carried out for 5 h in a temperature controlled incubator at ca.
37 °C (Barworld scientiﬁc Ltd., UK) using an orbital microplate
shaker at 100 rpm (Barworld scientiﬁc Ltd., UK). At the end of
the incubation period, 50 μL aliquots of plasma or buﬀer were
transferred into a 96-well deep plate and the composition in each
well was balanced with control ﬂuid (50 μL), such that the
volume of buﬀer to plasma is the same. Sample extraction was
performed by the addition of 200 μL of acetonitrile containing an
appropriate internal standard. Samples were allowed to mix for
1 min and then centrifuged at 3000 rpm in 96-well blocks for
15min (Allegra X12-R, BeckmanCoulter, USA) after which 150μL
of supernatant was removed to 50 μL of water. All samples were
analyzed by UPLC-MS/MS on a Quattro Premier XE Mass
Spectrometer (Waters Corporation, USA). The unbound frac-
tion was determined as the ratio of the peak area in buﬀer to that
in plasma.
PAMPA Assay. The permeability was performed using a 96-
well precoated BD Gentest PAMPA plate (BD Biosciences, U.K.).
Each well was divided into two chambers: donor and acceptor,
separated by a lipid-oil-lipid trilayer constructed in a porous ﬁlter.
The eﬀective permeability, Pe, of the compound was measured at
pH 7.4. Stock solutions (5 mM) of the compound were prepared
in DMSO. The compound was then further diluted to 10 μM in
phosphate buﬀered saline at pH 7.4. The ﬁnal DMSO concen-
tration did not exceed 5% v/v. The compound dissolved in
phosphate buﬀered saline was then added to the donor side of the
membrane, and phosphate buﬀered saline without compound
was added to the acceptor side. The PAMPA plate was left at
room temperature for 5 h; after which time, an aliquot (100 μL)
was then removed from both acceptor and donor compartments
and mixed with acetonitrile (80 μL) containing an internal stan-
dard: donepezil at 50 ng/mL). The samples were centrifuged
(10 min, 5 °C, 3270g) to sediment precipitated protein and
sealed prior to UPLC-MS/MS analysis using a Quattro Premier
XE (Waters Corp, USA). Pe was calculated as shown in the
below equation.
= × − −
× + ×
t
A t
Pe (nm/s) 107 ln[1 CA( )/Cequi]
[ (1/VD 1/VA) ]
where CA(t) = peak area of compound present in acceptor well
at time (t) = 18 000 s; Cequi = [CD(t) × VD + CA(t) × VA]/
(VD+VA);A = ﬁlter area; VD= donor well volume; VA= acceptor
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well volume; t = incubation time; CD(t) = peak area of
compound present in donor well at time (t) = 18 000 s. Recovery
of compound from donor and acceptor wells was calculated, and
data was only accepted when recovery exceeded 70%.
Animal Care Assurance.All mouse studies performed at the
University of Dundee were performed under the authority of a
project license (PPL70/8346) issued by the Home Oﬃce under
the Animals (Scientiﬁc Procedures) Act 1986, as amended in
2012 (and in compliance with EUDirective EU/2010/63). License
applications are approved by the University’s Ethical Review
Committee (ERC) before submission to the Home Oﬃce. The
ERC develops and oversees policy on all aspects of the use of
animals on University premises and is a subcommittee of the
University Court, its highest governing body.
Mouse Pharmacokinetics. Test compound was dosed as a
bolus solution intravenously at 3 mg free base/kg (dose volume:
5 mL/kg; dose vehicle: 10% DMSO; 40% PEG400; 50% saline)
to female C57Bl/6 mice (n = 3) or dosed orally by gavage as a
suspension at 10 or at 5, 30, or 100 mg free base/kg (dose
volume: 10 mL/kg; dose vehicle: 1.0% carboxy methyl cellulose)
to female C57Bl/6 mice (n = 3/dose level). Blood samples
were taken from each mouse tail vein at predetermined time
points postdose, mixed with nine volumes of distilled water, and
stored frozen until UPLC-MS/MS analysis. Pharmacokinetic
parameters were derived from the blood concentration time
curve using PK Solutions software v 2.0 (Summit Research
Services, USA).
Strains and Media. Mycobacterium tuberculosis H37Rv
(ATCC 27294) was used for all work with this organism unless
otherwise indicated. The activity of the compound on cell
wall synthesis and the bc1 complex was measured using the
piniBAC reporter strain and the cydC::aph strains, respectively,
using previously described methods.35,45 Broth-based medium
(7H9/ADC/Tw) for MTb consisted of Middlebrook 7H9
(Becton Dickinson) supplemented with 10% ADC [albumin
(50 g/L)/dextrose (20 g/L)/NaCl (8.1 g/L)], 0.2% glycerol] and
0.05%Tween 80. Solid growthmedium forMTbwasMiddlebrook
7H11 (Becton Dickinson) supplemented with OADC [ADC with
0.06% oleic acid]. Potencies of compounds by MIC determi-
nation were performed as previously described.45 The ΔndhA
strain was generated by insertion of the aph gene into the native
BamHI restriction site 873 nucleotides downstream of the start
codon using the previously described suicide vector method46 to
eﬀect legitimate recombination in MTb.
Measurement of Intracellular ATP Levels. MTb H37Rv
was grown to early log phase (OD650 nm of 0.2) and diluted 20-
fold in the same medium (7H9/ADC/Tw). 100 μL aliquots of
cells were added to each well of sterile white polystyrene 96-well
plates (Corning Inc., Corning, NY) containing 2 μL drug dilutions
in DMSO in triplicate. ATP was measured at diﬀerent time
points as indicated by a bioluminescent assay using the BacTiter-
Glo reagent (Promega, Madison, WI) as recommended by the
manufacturer.
Bioenergetics. The extracellular ﬂux analysis assays were
performed as described previously.21,36 In short, M. tuberculosis
H37Rv were grown in 7H9 (10% OADC, 0.01% tyloxapol) to an
OD of 0.8. Bacilli were pelleted, suspended in unbuﬀered carbon-
source-free XF 7H9 media, and seeded into the XF culture plate,
at a density of 2 × 106 bacilli/well. During the XF screen, the
oxygen consumption rate (OCR) was measured, noninvasively
and in real time. OCR data points are representative of the aver-
age OCR during 3 min of continuous measurement in the tran-
sient microchamber, with the error being calculated from the
OCRmeasurements taken from eight replicate wells by theWave
Desktop 2.3 software (Agilent). During the assay carbon sources
(glucose and palmitate at a ﬁnal concentration of 0.2%), the
mercapto-quinazolinones (Compounds 1 and 7 at ﬁnal con-
centrations of 39 and 45 μM, respectively) and CCCP
(ﬁnal concentration of 3 μM) were added to the assay media
at the indicated time.
Inverted Membrane Vesicle (IMV). IMVs were isolated,
and the ATP generation assay was performed as described pre-
viously.36 In brief, MTb mc26230 (cultured in 7H9, 0.01%
tyloxapol, 10% OADC, 0.2% casamino acids, and 24 μg/mL
pantothenic acid) were collected via centrifugation, incubated
with lysozyme, and lysed via bead beating in a buﬀer containing
10 mM HEPES, 50 mM KCl, 5 mM MgCl2, and 10% glycerol.
IMVs were isolated by diﬀerential centrifugation. The ATP
synthesis assay was performed using a Roche Bioluminescence
Assay Kit CL II. Membrane vesicles were provided either 250 μM
NADHor 1mM succinate as an electron donor, 50 μMADP, and
5 mM phosphate in the above buﬀer containing the luciferase/
luciferin reagents. Luminescence was measured in a 384-well
plate using a BioTek Synergy H4 plate reader.
Recombinant Rv1854c Puriﬁcation. The ORF corre-
sponding to Rv1854c was codon optimized for E. coli,
synthesized (ThermoFisher), and cloned between the NcoI
and HindIII sites of pMALc5x, aﬀording a vector for the IPTG-
inducible overexpression of MtNdh with an N-terminal maltose-
binding protein (MBP) fusion tag. This vector was transformed
into E. coli BL21 (DE3) pLysS, and protein expression was
achieved in 1 L of media (ZYM + 0.1% glucose, 0.1% glycerol,
2 mM MgSO4, 34 μg/mL chloramphenicol, 50 μg/mL
carbenicillin) following induction with 0.3 mM IPTG at 37 °C
for 4 h. Cells were harvested, resuspended in 40 mL of buﬀer A
(50mMHEPES, 100mMKPO4, pH 7.1, 5% (w/v) glycerol) with
added 5 U/mL DNase, complete protease inhibitor, 5 μM FAD,
10 mMMgCl2, and 0.25% CHAPS, and sonicated on ice to lyse.
Following centrifugation at 20 000g for 30 min, the soluble
fraction was incubated with 2 mL of settled volume of pre-
equilibrated (buﬀer A + 0.25%CHAPS) amylose resin for 30min
at 4 °C and then applied to a gravity ﬂow column. The resin was
washed with 15 CV buﬀer A + 0.25% CHAPS and then 15 CV
buﬀer A without CHAPS. Bound protein was eluted with 10 mL
of buﬀer A + 20 mM maltose. The same puriﬁcation procedure
was repeated twice on the initial resin ﬂow-throughs; all eluates
were combined and concentrated using spin columns. The con-
centrated prep was then passed through a Superdex 75 10/300
column (running buﬀer was buﬀer A), and relevant fractions
were collected and concentrated. Aliquots of the resulting weakly
yellow solution were ﬂash frozen and stored at −80 °C until
needed. Protein concentration was measured by spectrophoto-
metric ﬂavin (FAD) analysis, as described in ref 47.
NdhActivity Assays.MtNdh catalytic activity was measured
by monitoring NADH oxidation at 340 nm (ε = 6220M−1 cm−1)
in a UV−vis spectrophotometer at RT. Reactions (1 mL) con-
sisted of 0.1 M HEPES, pH 7.0, 10% DMSO, 0.1−0.5 nM
recombinant MBP-MtNdh, and varying concentrations of Q2
and NADH. Reactions were started by addition of NADH, fol-
lowing ∼1 min preincubation of all other reaction components.
Kinetic data was taken at steady state within the ﬁrst 1 min of
the reaction. Background NADH oxidation in the absence of Q2
was measured (typically <5% of rate with Q2 present) and
subtracted from all subsequent measurements, as required. All
kinetic data was plotted and analyzed using GraphPad Prism
software.
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